lung cancer

[Scientific Reports] Researchers developed a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identify genes significantly differentially expressed under hypoxia in four LUAD cell lines.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Cell Death Discovery] Investigators suggested that treatment with vascular endothelial growth factor receptor 2 (VEGFR2)-tyrosine kinase inhibitors upregulated ADRB2 expression in NSCLC cells.

[Cell Death & Disease] Scientists found that ERβ could promote NSCLC cell invasion via increasing the circular RNA (circRNA), circ-TMX4, expression via directly binding to the 5′ promoter region of its host gene TMX4.

[Scientific Reports] Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.

[Turning Point Therapeutics] Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s Investigational New Drug application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.